On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...
"Patients have already been exposed to these large language models (LLMs). Yes, they are aware of the risks, but they are also very aware...
"And what I was really surprised about was that everybody was doing data collection in a different way. And I kept thinking that, gosh,...